These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24621837)

  • 21. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
    Thadani U
    Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranolazine-induced Repolarization Changes: A Case Report.
    Kumthekar A; Cossarini F; Shih JC; Taub CC; Massera D
    Am J Med; 2015 Jul; 128(7):e3-5. PubMed ID: 25660248
    [No Abstract]   [Full Text] [Related]  

  • 23. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.
    Sossalla S; Wagner S; Rasenack EC; Ruff H; Weber SL; Schöndube FA; Tirilomis T; Tenderich G; Hasenfuss G; Belardinelli L; Maier LS
    J Mol Cell Cardiol; 2008 Jul; 45(1):32-43. PubMed ID: 18439620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction.
    Wu Y; Song Y; Belardinelli L; Shryock JC
    J Pharmacol Exp Ther; 2009 Aug; 330(2):550-7. PubMed ID: 19403851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of ranolazine in the prevention and treatment of postoperative atrial fibrillation in patients undergoing cardiac surgery.
    Tsu LV; Lee S
    Ann Pharmacother; 2014 May; 48(5):633-7. PubMed ID: 24523397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ranolazine in the prevention of anthracycline cardiotoxicity.
    Corradi F; Paolini L; De Caterina R
    Pharmacol Res; 2014 Jan; 79():88-102. PubMed ID: 24269342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
    Ling H; Packard KA; Burns TL; Hilleman DE
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In regard to the TERISA trial.
    Golwala H
    J Am Coll Cardiol; 2014 Jul; 64(4):420. PubMed ID: 25060380
    [No Abstract]   [Full Text] [Related]  

  • 29. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
    Fredj S; Sampson KJ; Liu H; Kass RS
    Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply: In regard to the TERISA trial.
    Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Yue P; Ben-Yehuda O; Belardinelli L; Chaitman BR
    J Am Coll Cardiol; 2014 Jul; 64(4):420-1. PubMed ID: 25060381
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest.
    Fumagalli F; Russo I; Staszewsky L; Li Y; Letizia T; Masson S; Novelli D; Rocchetti M; Canovi M; Veglianese P; Gobbi M; Latini R; Zaza A; Ristagno G
    Heart Rhythm; 2014 Sep; 11(9):1641-7. PubMed ID: 24858811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranolazine attenuates behavioral signs of neuropathic pain.
    Gould HJ; Garrett C; Donahue RR; Paul D; Diamond I; Taylor BK
    Behav Pharmacol; 2009 Dec; 20(8):755-8. PubMed ID: 19773645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit.
    Hale SL; Kloner RA
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):249-55. PubMed ID: 17220471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Late sodium current and calcium overload--pathogenesis and adequate treatment].
    Jacobshagen C
    Dtsch Med Wochenschr; 2013 Apr; 138(16):842-7. PubMed ID: 23589047
    [No Abstract]   [Full Text] [Related]  

  • 36. Late sodium current inhibition alone with ranolazine is sufficient to reduce ischemia- and cardiac glycoside-induced calcium overload and contractile dysfunction mediated by reverse-mode sodium/calcium exchange.
    Soliman D; Wang L; Hamming KS; Yang W; Fatehi M; Carter CC; Clanachan AS; Light PE
    J Pharmacol Exp Ther; 2012 Nov; 343(2):325-32. PubMed ID: 22879384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
    Stone PH
    Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report.
    Kaliebe JW; Murdock DK
    WMJ; 2009 Oct; 108(7):373-5. PubMed ID: 19886587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranolazine is effective for acute or chronic ischemic dysfunction with heart failure.
    Nanda S; Martinez MW; Dey T
    J Am Coll Cardiol; 2010 Aug; 56(10):822; author reply 822. PubMed ID: 20797499
    [No Abstract]   [Full Text] [Related]  

  • 40. [New pharmacological approaches to ischemic heart disease].
    Raddino R; Della Pina P; Gorga E; Brambilla G; Regazzoni V; Gavazzoni M; Dei Cas L
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):50S-54S. PubMed ID: 23096376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.